Published in Expert Opin Investig Drugs on March 30, 2011
Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther (2011) 1.10
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08
Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am (2012) 1.07
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res (2014) 0.98
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol (2013) 0.93
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel) (2011) 0.90
Targeting the IGF-1R: The Tale of the Tortoise and the Hare. Front Endocrinol (Lausanne) (2015) 0.87
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther (2012) 0.82
Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncol Rev (2013) 0.79
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res (2014) 0.79
Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone. Cancer Microenviron (2013) 0.79
Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications. Int J Oncol (2011) 0.79
Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. Oncotarget (2014) 0.78
Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Ups J Med Sci (2012) 0.77
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget (2016) 0.76
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer (2017) 0.76
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment. Front Oncol (2015) 0.76
Insulin-like growth factor-1 receptor inhibitors: a potential cancer treatment: patent highlight. ACS Med Chem Lett (2012) 0.75
Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening. Acta Naturae (2013) 0.75
IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. Am J Cancer Res (2015) 0.75
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo. Oncoimmunology (2017) 0.75
Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer. Front Oncol (2016) 0.75
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res (2007) 0.92
Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry. Mt Sinai J Med (2010) 0.77